Repligen Earnings
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Oct 27, 2026
Fiscal period
Sep/2026
EPS estimate
$0.46
Repligen earnings summary
Repligen is scheduled to report Sep/2026 earnings on Oct 27, 2026, with analysts expecting EPS of $0.46. In its most recent report on Jul 29, 2026 (Q2 2026), RGEN posted EPS of $0.09. Revenue for the quarter was $204.1 million.
Quarterly EPS is down 65.4% from the same quarter a year earlier. Across the last 16 reports, RGEN shares moved an average of 7.3% (in either direction) in the first trading session after results, rising 7 times and falling 9 times.
Summary generated from market data by MetaCap's automated system. Methodology
RGEN earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Jul 29, 2026 | — | $0.09 | — | +16.2% |
| May 6, 2026 | — | $0.15 | — | -16.7% |
| Feb 26, 2026 | — | $0.24 | — | -6.8% |
| Nov 4, 2025 | — | $0.26 | — | +6.7% |
| Aug 7, 2025 | — | $0.26 | — | +11.6% |
| Apr 29, 2025 | — | $0.10 | — | -12.9% |
| Mar 14, 2025 | — | $-0.61 | — | -7.0% |
| Nov 18, 2024 | — | $-0.01 | — | +5.6% |
| Jul 30, 2024 | — | $0.10 | — | +2.2% |
| May 1, 2024 | — | $0.06 | — | -0.1% |
| Feb 22, 2024 | — | $-0.29 | — | -0.5% |
| Oct 31, 2023 | — | $0.30 | — | -1.9% |
| Aug 2, 2023 | — | $0.35 | — | -0.4% |
| May 2, 2023 | — | $0.27 | — | -5.1% |
| Feb 22, 2023 | — | $0.84 | — | +8.4% |
| Nov 1, 2022 | — | $0.71 | — | +14.3% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.